Results 101 to 110 of about 161,483 (243)

Comparison Between Upfront Surgery and Preoperative Chemotherapy for CY1P0 Gastric Cancer: A Japanese Sub‐Analysis of CONVO‐GC‐1

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Radical gastrectomy, followed by adjuvant chemotherapy has been a common practice in Japan for peritoneal lavage cytology‐positive (CY1) but peritoneal dissemination‐negative (P0) stage IV gastric cancer. This study aimed to clarify the differences in treatment outcomes between upfront surgery and preoperative chemotherapy, followed
Kenichiro Furukawa   +12 more
wiley   +1 more source

Multifactor Risk Stratification for Post‐Transplant Alcohol Relapse Using Abstinence, Psychosocial, and Socioeconomic Factors

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Alcohol relapse after liver transplantation is difficult to predict using abstinence duration alone. We developed a multifactor model integrating abstinence duration, psychosocial risk (SIPAT), and socioeconomic context (AUC 0.70). This approach may support individualized risk assessment and tailored follow‐up intensity; external validation is needed ...
Ayato Obana   +9 more
wiley   +1 more source

Semiparametric Estimation of Single-Index Transition Intensities [PDF]

open access: yes
This research develops semiparametric kernel-based estimators of state-specific conditional transition intensitiesm, hs (y|x), for duration models with right-censoring and/or multiple destinations (competing risks).
Tue Gørgens
core  

Management Strategies for Disappearing Colorectal Liver Metastases After Systemic Chemotherapy: Long‐Term Outcomes and Preoperative Prediction of ‘True Complete Response’

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Determining whether to resect disappearing liver metastases (DLMs) after chemotherapy for colorectal liver metastases (CRLMs) remains challenging. Methods Patients who underwent hepatectomy after systemic chemotherapy for initially unresectable CRLMs were reviewed. True complete response (CR) was defined as either resected DLMs with
Taihei Soma   +9 more
wiley   +1 more source

“Intrapericardial Approach” for Venous Outflow Reconstruction in Living‐Donor Liver Transplantation for Budd‐Chiari Syndrome: Surgical Techniques and LongTerm Outcomes

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Unlike deceased‐donor liver transplantation, living‐donor liver transplantation (LDLT) for Budd‐Chiari Syndrome (BCS) presents distinctive challenges in hepatic venous (HV)‐outflow reconstruction because diseased HV–inferior vena cava (IVC) cannot be entirely replaced with healthy donor vessels.
Koichiro Hata   +4 more
wiley   +1 more source

Skew-Normal Inflated Models: Mathematical Characterization and Applications to Medical Data with Excess of Zeros and Ones

open access: yesMathematics
The modeling of data involving proportions, confined to a unit interval, is crucial in diverse research fields. Such data, expressing part-to-whole relationships, span from the proportion of individuals affected by diseases to the allocation of resources
Guillermo Martínez-Flórez   +3 more
doaj   +1 more source

An Empirical Investigation of Biased Survey Data and an Attempted Cure [PDF]

open access: yes
In this paper I investigate response bias in survey data on annual driving mileage and evaluate the performance of a proposed remedy, Orbit. Individuals systematically exaggerate their deviation from the sample average, and using the self-reported data ...
James E. Prieger
core  

Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5‐Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single‐Institute Propensity Score Analysis

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Although neoadjuvant chemotherapy with fluorouracil, cisplatin, and docetaxel (NAC‐DCF) is the current standard neoadjuvant regimen for esophageal squamous cell carcinoma, its substantial toxicity underscores the need to identify patients who derive the greatest benefit.
Eiji Higaki   +9 more
wiley   +1 more source

Clinical Significance of PD‐L1 and HLA Expression in Esophageal Squamous Cell Carcinoma in Response to Immunotherapy

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This study evaluated immune‐related biomarkers in esophageal squamous cell carcinoma treated with immune checkpoint inhibitors after postoperative recurrence. PD‐L1 expression in tumor‐associated macrophages and tumor cells, together with HLA class I downregulation and HLA‐DR expression, were associated with favorable responses to immunotherapy.
Kosuke Kanemitsu   +9 more
wiley   +1 more source

Navigating the Post‐BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies.
Maximilian Al‐Bazaz   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy